The National Strategy for Gene and Cell Therapies (GCT) is driving innovation by supporting cutting-edge research that transforms gene and cell-based therapies from bench to bedside.
Key Deadlines:
- Track 1 Applications: February 17, 2025, at 1:00 PM
- Track 2 Applications: March 24, 2025, at 1:00 PM
What is Being Funded?
Visionary translational projects advancing process development, platform technologies, diagnostic approaches, and therapies for monogenic disorders, autoimmune diseases, cancer and beyond - focused on product development with a strategic aim for licensing and spin-off creation:
- Gene therapies for rare and complex diseases
- Cell-based therapies, including immune and stem cell treatments
- Interdisciplinary innovations that bridge cutting-edge technology and clinical application
- NEW: Clinical studies up to Phase IIb
What the SPARK National Program Offers
The SPARK National Program provides tailored support to drive your translational projects forward:
- Milestone-Based Funding to accelerate research and development
- Comprehensive Guidance and Expertise using the proven SPARK Method
- Exclusive Access to workshops, webinars, and the global SPARK network
Why SPARK?
SPARK is a unique model to bridge the gap between academic discoveries and patient care. A testament to the successful SPARK program is the FDA approval of Attruby for Life-Threatening Heart Disease. Today, the SPARK Global Network spans over 60 institutions in 23 countries, with hundreds of translational programs that transcend borders.
Sound interesting?
Online Info Session Dates:
- January 16th | 9:30–10:30
- January 28th | 13:00–14:00
The Teams link will be posted here
Application
Apply here!
For detailed guidelines and application procedures, visit the DLR page
Download the application form here
